Triamcinolone acetonide in ocular therapeutics

被引：111
作者：
Jermak, C. M.
Dellacroce, J. T.
Heffez, J.
Peyman, G. A.
机构：
[1] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA
[2] Retina Consultants Westren New York, Buffalo, NY USA
来源：
SURVEY OF OPHTHALMOLOGY | 2007年 / 52卷 / 05期
关键词：
intravitreal steroid; Kenalog; periocular steroid; sub-tenon steroid; triamcinolone acetonide;
D O I：
10.1016/j.survophthal.2007.06.004
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Triamcinolone acetonide has been effectively used in ocular therapeutics for over 50 years. Its use has increased dramatically in recent years for periocular and intraocular treatment of retinal vasculature disease and uveitis. This comprehensive review discusses the pharmacokinetics of triamcinolone acetonide and summarizes its uses in a number of diseases, both intraocular and extraocular. It discusses side effects and their management. Finally, it discusses the controversy over its use.
引用
收藏
页码：503 / 522
页数：20
相关论文
共 141 条
[1]   Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis [J].
Alldredge, CD ;
Garretson, BR .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2003, 23 (01) :113-116
[2]   Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome [J].
Andrade, RE ;
Muccioli, C ;
Farah, ME ;
Nussenblatt, RB ;
Belfort, R .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (03) :572-574
[3]   A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration [J].
Argenti, D ;
Jensen, BK ;
Hensel, R ;
Bordeaux, K ;
Schleimer, R ;
Bickel, C ;
Heald, D .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (07) :770-780
[4]   Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema [J].
Audren, F ;
Tod, M ;
Massin, P ;
Benosman, R ;
Haouchine, B ;
Erginay, A ;
Caulin, C ;
Gaudric, A ;
Bergmann, JF .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (10) :3435-3441
[5]   Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial [J].
Audren, Francois ;
Erginay, Ali ;
Haouchine, Belkacem ;
Benosman, Rym ;
Conrath, John ;
Bergmann, Jean-Francois ;
Gaudric, Alain ;
Massin, Pascale .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 2006, 84 (05) :624-630
[6]  
Bakri SJ, 2003, OPHTHALMIC SUR LA IM, V34, P386
[7]   Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion [J].
Bashshur, ZF ;
Ma'luf, RN ;
Allam, S ;
Jurdi, FA ;
Haddad, RS ;
Noureddin, BN .
ARCHIVES OF OPHTHALMOLOGY, 2004, 122 (08) :1137-1140
[8]  
BECKER B, 1971, AM J OPHTHALMOL, V71, P1
[9]   Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection [J].
Beer, PM ;
Bakri, SJ ;
Singh, RJ ;
Liu, WG ;
Peters, GB ;
Miller, M .
OPHTHALMOLOGY, 2003, 110 (04) :681-686
[10]   Intravitreal triamcinolone for refractory pseudophakic macular edema [J].
Benhamou, N ;
Massin, P ;
Haouchine, B ;
Audren, F ;
Tadayoni, R ;
Gaudric, A .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 135 (02) :246-249
12345678910